Fu Yang1,2,3,4, Jing Wen2,3,4, Kongjia Luo2,3,4, Jianhua Fu5,6,7. 1. Department of Thoracic Surgery, Shanghai Jiaotong University First People's Hospital, 200080, Shanghai, People's Republic of China. 2. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 510060, Guangzhou, People's Republic of China. 3. Guangdong Esophageal Cancer Research Institute, 510060, Guangzhou, People's Republic of China. 4. Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, 510060, Guangzhou, People's Republic of China. 5. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 510060, Guangzhou, People's Republic of China. fujh@sysucc.org.cn. 6. Guangdong Esophageal Cancer Research Institute, 510060, Guangzhou, People's Republic of China. fujh@sysucc.org.cn. 7. Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, 510060, Guangzhou, People's Republic of China. fujh@sysucc.org.cn.
Abstract
BACKGROUND: Glutathione S-transferase mu 3 (GSTM3) plays a crucial role in tumor progression in various cancers. However, the relationship between GSTM3 expression and the clinical prognosis of esophageal squamous cell carcinoma (ESCC) has not been studied to date. We aimed to characterize the role of GSTM3 in predicting postoperative prognosis of ESCC patients. METHODS: In the retrospective study, GSTM3 mRNA levels in 184 ESCC tissues and matched 43 adjacent nontumorous tissues were measured by quantitative real-time PCR. GSTM3 protein levels in 247 ESCC tissues were measured by immunohistochemistry. RESULTS: Downregulation of GSTM3 occurred in 62.8 % of primary ESCC tissues compared with their nontumor counterparts. Patients with low GSTM3 expression tended to exhibit an increased rate of poor differentiation in both the mRNA cohort (p = 0.024) and protein cohort (p = 0.004). In the mRNA cohort, low GSTM3 expression was associated with unfavorable 3-year disease-free survival (DFS) (39.2 % vs. 57.4 %) and 5-year DFS (26.8 % vs. 45.1 %) (p = 0.023). The result was confirmed in the protein cohort. Patients with low GSTM3 expression had unfavorable 3-year disease-free survival (DFS) (18.7 % vs. 33.5 %) and 5-year DFS (5.3 % vs. 30.5 %) (p = 0.006). Cox multivariate analysis revealed that GSTM3 expression was an independent prognostic factor. CONCLUSIONS: The findings of the present study provide evidence that GSTM3 may function as a tumor suppressor in ESCC and represents a potential novel prognostic biomarker for disease-free survival for resected ESCC patients.
BACKGROUND:Glutathione S-transferase mu 3 (GSTM3) plays a crucial role in tumor progression in various cancers. However, the relationship between GSTM3 expression and the clinical prognosis of esophageal squamous cell carcinoma (ESCC) has not been studied to date. We aimed to characterize the role of GSTM3 in predicting postoperative prognosis of ESCC patients. METHODS: In the retrospective study, GSTM3 mRNA levels in 184 ESCC tissues and matched 43 adjacent nontumorous tissues were measured by quantitative real-time PCR. GSTM3 protein levels in 247 ESCC tissues were measured by immunohistochemistry. RESULTS: Downregulation of GSTM3 occurred in 62.8 % of primary ESCC tissues compared with their nontumor counterparts. Patients with low GSTM3 expression tended to exhibit an increased rate of poor differentiation in both the mRNA cohort (p = 0.024) and protein cohort (p = 0.004). In the mRNA cohort, low GSTM3 expression was associated with unfavorable 3-year disease-free survival (DFS) (39.2 % vs. 57.4 %) and 5-year DFS (26.8 % vs. 45.1 %) (p = 0.023). The result was confirmed in the protein cohort. Patients with low GSTM3 expression had unfavorable 3-year disease-free survival (DFS) (18.7 % vs. 33.5 %) and 5-year DFS (5.3 % vs. 30.5 %) (p = 0.006). Cox multivariate analysis revealed that GSTM3 expression was an independent prognostic factor. CONCLUSIONS: The findings of the present study provide evidence that GSTM3 may function as a tumor suppressor in ESCC and represents a potential novel prognostic biomarker for disease-free survival for resected ESCC patients.
Authors: Stephan Meding; Benjamin Balluff; Mareike Elsner; Cédrik Schöne; Sandra Rauser; Ulrich Nitsche; Matthias Maak; Alexander Schäfer; Stefanie M Hauck; Marius Ueffing; Rupert Langer; Heinz Höfler; Helmut Friess; Robert Rosenberg; Axel Walch Journal: J Pathol Date: 2012-05-23 Impact factor: 7.996
Authors: J Wen; H Yang; M Z Liu; K J Luo; H Liu; Y Hu; X Zhang; R C Lai; T Lin; H Y Wang; J H Fu Journal: Ann Oncol Date: 2014-06-06 Impact factor: 32.976
Authors: Neal D Freedman; Christian C Abnet; Michael F Leitzmann; Traci Mouw; Amy F Subar; Albert R Hollenbeck; Arthur Schatzkin Journal: Am J Epidemiol Date: 2007-04-09 Impact factor: 4.897
Authors: Juan Zhang; Yan Li; Juan Zou; Chun-Tian Lai; Tian Zeng; Juan Peng; Wen-da Zou; Bei Cao; Dan Liu; Li-Yu Zhu; Hui Li; Yu-Kun Li Journal: Front Oncol Date: 2022-07-28 Impact factor: 5.738